Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV – Get Free Report) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 328 shares, an increase of 150.4% from the April 15th total of 131 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 713 shares, the short-interest ratio is currently 0.5 days.
Mosaic ImmunoEngineering Stock Performance
Shares of OTCMKTS:CPMV remained flat at $0.69 during midday trading on Friday. 6 shares of the stock traded hands, compared to its average volume of 398. Mosaic ImmunoEngineering has a one year low of $0.25 and a one year high of $1.05. The stock has a market cap of $5.03 million, a P/E ratio of -6.95 and a beta of -0.68. The business’s 50 day moving average price is $0.65 and its 200 day moving average price is $0.58.
Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) last released its quarterly earnings results on Wednesday, April 15th. The company reported ($0.03) earnings per share for the quarter.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
See Also
- Five stocks we like better than Mosaic ImmunoEngineering
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
- 3 AI Data Center Stocks Worth Watching for Capital Rotation
- McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
